Navega Therapeutics
Fernando obtained his PharmD degree at University of Granada and his PhD at University of Murcia. After postdoc training at UCSD and the Scripps, he leverages his pharmaceutical and industry background to provide medical oversight and strategic direction.
Navega Therapeutics
Navega Therapeutics has developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific, and long-lasting. Navega Therapeutics has imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way.